Prophylactic statins as a possible method to decrease bubble formation in diving | Canada Hyperbarics Skip to main content
RCT Aviat Space Environ Med 2007

Prophylactic statins as a possible method to decrease bubble formation in diving

Duplessis C, Fothergill D, Schwaller D, Hughes L, Gertner J — Aviat Space Environ Med, 2007

Tier 1, Curated

Manually reviewed and included in the Canada Hyperbarics research database.

Summary

What Researchers Did

Researchers investigated if taking 80 mg of atorvastatin for four days could reduce bubble formation in 16 military divers after a simulated hyperbaric chamber dive.

What They Found

The study found that 80 mg of atorvastatin taken for four days did not reduce the number of intravascular bubbles observed after a 60-foot, 80-minute dry chamber dive (z = 0.00, p = 1.00, n=16). While the medication significantly lowered LDL cholesterol from 107.6 to 79.3 mg/dl and total cholesterol from 175 to 147 mg/dl, this did not lead to fewer bubbles. However, factors like age, cholesterol levels, potassium, and calcium showed positive correlations with bubble grades in the placebo group.

What This Means for Canadian Patients

This research suggests that Canadian divers should not rely on prophylactic 80 mg atorvastatin for four days to prevent bubble formation, which can lead to decompression sickness. Instead, divers should continue to follow established diving safety guidelines and protocols to minimize their risk of decompression sickness.

Canadian Relevance

Although this study was not conducted in Canada, it covers decompression sickness, which is a Health Canada-recognized indication for hyperbaric oxygen therapy.

Study Limitations

The study involved a small number of participants and only investigated one specific dose and duration of atorvastatin.

Was this summary helpful?

Study Details

Study Type RCT
Category Decompression Sickness
Source Pubmed
PubMed ID 17484348
Year Published 2007
Journal Aviat Space Environ Med
MeSH Terms Adult; Atorvastatin; Chemoprevention; Decompression Sickness; Diving; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Nitric Oxide; Pyrroles; Surface-Active Agents

Cite This Study

Share

Find a Canadian Clinic Treating Decompression Sickness

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.